Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

HLA and KIR Associations of Cervical Neoplasia.

Bao X, Hanson AL, Madeleine MM, Wang SS, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, Franco EL, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Garland SM, Tabrizi SN, Wentzensen N, Sitas F, Trimble C, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA, Duncan EL, Sun YP, Leo PJ.

J Infect Dis. 2018 Nov 5;218(12):2006-2015. doi: 10.1093/infdis/jiy483.

2.

Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials.

Safaeian M, Castellsagué X, Hildesheim A, Wacholder S, Schiffman MH, Bozonnat MC, Baril L, Rosillon D; Costa Rica HPV Vaccine Trial and the PATRICIA study groups.

J Infect Dis. 2018 Jun 5;218(1):84-94. doi: 10.1093/infdis/jiy112.

3.

Quantification of Human Microbiome Stability Over 6 Months: Implications for Epidemiologic Studies.

Sinha R, Goedert JJ, Vogtmann E, Hua X, Porras C, Hayes R, Safaeian M, Yu G, Sampson J, Ahn J, Shi J.

Am J Epidemiol. 2018 Jun 1;187(6):1282-1290. doi: 10.1093/aje/kwy064.

4.

Correction: Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study.

Leo PJ, Madeleine MM, Wang S, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Hallmans G, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, Franco EL, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Trimble CL, Garland S, Tabrizi SN, Wentzensen N, Sitas F, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA.

PLoS Genet. 2018 Mar 1;14(3):e1007257. doi: 10.1371/journal.pgen.1007257. eCollection 2018 Mar.

5.

T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study.

Lang Kuhs KA, Lin SW, Hua X, Schiffman M, Burk RD, Rodriguez AC, Herrero R, Abnet CC, Freedman ND, Pinto LA, Hamm D, Robins H, Hildesheim A, Shi J, Safaeian M.

PLoS One. 2018 Jan 31;13(1):e0178167. doi: 10.1371/journal.pone.0178167. eCollection 2018.

6.

Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies.

Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, Schiffman M, Rodriguez AC, Chanock S, Jimenez S, Schussler J, Gail MH, Safaeian M, Kemp TJ, Cortes B, Pinto LA, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group.

Vaccine. 2018 Aug 6;36(32 Pt A):4774-4782. doi: 10.1016/j.vaccine.2017.12.078. Epub 2018 Feb 1.

7.

Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.

Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, Schiller J, Schiffman MT, Rodriguez AC, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx158.

8.

Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study.

Leo PJ, Madeleine MM, Wang S, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Hallmans G, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, Franco EL, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Trimble CL, Garland S, Tabrizi SN, Wentzensen N, Sitas F, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA.

PLoS Genet. 2017 Aug 14;13(8):e1006866. doi: 10.1371/journal.pgen.1006866. eCollection 2017 Aug. Erratum in: PLoS Genet. 2018 Mar 1;14 (3):e1007257.

9.

Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States.

Van Dyke AL, Lang Kuhs KA, Shiels MS, Koshiol J, Trabert B, Loftfield E, Purdue MP, Wentzensen N, Pfeiffer RM, Katki HA, Hildesheim A, Kemp TJ, Pinto LA, Chaturvedi AK, Safaeian M.

PLoS One. 2017 Jul 28;12(7):e0182359. doi: 10.1371/journal.pone.0182359. eCollection 2017.

10.

Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.

Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, Chaturvedi AK, Hildesheim A, Berndt SI, Safaeian M, Pinto L, Wentzensen N.

Int J Cancer. 2017 Feb 1;140(3):600-610. doi: 10.1002/ijc.30478. Epub 2016 Nov 7.

11.

Cancer risk among lung transplant recipients with cystic fibrosis.

Fink AK, Yanik EL, Marshall BC, Wilschanski M, Lynch CF, Austin AA, Copeland G, Safaeian M, Engels EA.

J Cyst Fibros. 2017 Jan;16(1):91-97. doi: 10.1016/j.jcf.2016.07.011. Epub 2016 Aug 15.

12.

Risk of Colorectal Cancer After Solid Organ Transplantation in the United States.

Safaeian M, Robbins HA, Berndt SI, Lynch CF, Fraumeni JF Jr, Engels EA.

Am J Transplant. 2016 Mar;16(3):960-7. doi: 10.1111/ajt.13549. Epub 2016 Jan 5.

13.

Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.

Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N.

J Infect Dis. 2016 May 1;213(9):1444-54. doi: 10.1093/infdis/jiv753. Epub 2015 Dec 21. Review.

14.

Quantitative Detection and Genotyping of Helicobacter pylori from Stool using Droplet Digital PCR Reveals Variation in Bacterial Loads that Correlates with cagA Virulence Gene Carriage.

Talarico S, Safaeian M, Gonzalez P, Hildesheim A, Herrero R, Porras C, Cortes B, Larson A, Fang FC, Salama NR.

Helicobacter. 2016 Aug;21(4):325-33. doi: 10.1111/hel.12289. Epub 2015 Dec 15.

15.

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, Jimenez S, Safaeian M, Struijk L, Schussler J, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group.

J Natl Cancer Inst. 2015 Oct 14;108(1). pii: djv302. doi: 10.1093/jnci/djv302. Print 2016 Jan.

16.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.

Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

17.

Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.

Gonzalez P, Hildesheim A, Herrero R, Katki H, Wacholder S, Porras C, Safaeian M, Jimenez S, Darragh TM, Cortes B, Befano B, Schiffman M, Carvajal L, Palefsky J, Schiller J, Ocampo R, Schussler J, Lowy D, Guillen D, Stoler MH, Quint W, Morales J, Avila C, Rodriguez AC, Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group.

Vaccine. 2015 Apr 27;33(18):2141-51. doi: 10.1016/j.vaccine.2015.03.015. Epub 2015 Mar 18.

18.

Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Lang Kuhs KA, Hildesheim A, Trabert B, Kemp TJ, Purdue MP, Wentzensen N, Katki HA, Pinto LA, Loftfield E, Safaeian M, Chaturvedi AK, Shiels MS.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):825-32. doi: 10.1158/1055-9965.EPI-14-1363. Epub 2015 Feb 23.

19.

A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.

Kemp TJ, Matsui K, Shelton G, Safaeian M, Pinto LA.

Hum Vaccin Immunother. 2015;11(2):337-46. doi: 10.4161/21645515.2014.990851.

20.

The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.

Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M.

J Natl Cancer Inst. 2015 Feb 2;107(3). pii: dju436. doi: 10.1093/jnci/dju436. Print 2015 Mar. No abstract available.

21.

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M.

Hum Vaccin Immunother. 2014;10(10):2965-74. doi: 10.4161/21645515.2014.972811.

22.

Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination.

Safaeian M, Rodriguez AC.

Am J Epidemiol. 2014 Dec 1;180(11):1076-81. doi: 10.1093/aje/kwu265. Epub 2014 Oct 29.

23.

Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.

LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M.

Vaccine. 2014 Oct 29;32(47):6303-11. doi: 10.1016/j.vaccine.2014.08.071. Epub 2014 Sep 16.

PMID:
25218297
24.

Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.

Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M; Costa Rica Vaccine Trial Group.

Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.

25.

Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma.

Safaeian M, Johnson LG, Yu K, Wang SS, Gravitt PE, Hansen JA, Carrington M, Schwartz SM, Gao X, Hildesheim A, Madeleine MM.

Front Oncol. 2014 Jun 19;4:119. doi: 10.3389/fonc.2014.00119. eCollection 2014.

26.

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2014 Dec 15;210(12):1890-9. doi: 10.1093/infdis/jiu357. Epub 2014 Jun 23.

27.

Number of human papillomavirus vaccine doses and condyloma.

Kreimer AR, Safaeian M, Hildesheim A.

JAMA. 2014 Jun 18;311(23):2439. doi: 10.1001/jama.2014.5009. No abstract available.

PMID:
24938569
28.

Logistic analysis of epidemiologic studies with augmentation sampling involving re-stratification and population expansion.

Li Y, Safaeian M, Robbins HA, Graubard BI.

Biostatistics. 2015 Jan;16(1):169-78. doi: 10.1093/biostatistics/kxu024. Epub 2014 Jun 6.

29.

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L.

J Infect Dis. 2014 Aug 15;210(4):517-34. doi: 10.1093/infdis/jiu139. Epub 2014 Mar 8.

30.

Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.

Robbins HA, Li Y, Porras C, Pawlita M, Ghosh A, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Gonzalez P, Schiller J, Lowy D, Esser M, Matys K, Quint W, van Doorn LJ, Herrero R, Pinto LA, Hildesheim A, Waterboer T, Safaeian M.

BMC Infect Dis. 2014 Mar 3;14:120. doi: 10.1186/1471-2334-14-120.

31.

Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.

Robbins HA, Kemp TJ, Porras C, Rodriguez AC, Schiffman M, Wacholder S, Gonzalez P, Schiller J, Lowy D, Poncelet S, Esser M, Matys K, Hildesheim A, Pinto LA, Herrero R, Safaeian M.

Front Oncol. 2014 Jan 13;3:328. doi: 10.3389/fonc.2013.00328. eCollection 2014 Jan 13.

32.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group.

Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203. Erratum in: Cancer Prev Res (Phila). 2016 Jan;9(1):116-7.

33.

From Papanicolaou to papillomaviruses: evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination.

Safaeian M, Sherman ME.

J Natl Cancer Inst. 2013 Oct 16;105(20):1524-6. doi: 10.1093/jnci/djt267. Epub 2013 Oct 4. No abstract available.

34.

Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.

Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, Rodriguez AC, Schiffman M, Quint W, Lowy DR, Porras C, Delvecchio C, Katki HA, Jimenez S, Safaeian M, Schiller J, Solomon D, Wacholder S, Herrero R, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2013 Nov 15;208(10):1643-52. doi: 10.1093/infdis/jit369. Epub 2013 Sep 6.

35.

Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk.

Safaeian M, Rajaraman P, Hartge P, Yeager M, Linet M, Butler MA, Ruder AM, Purdue MP, Hsing A, Beane-Freeman L, Hoppin JA, Albanes D, Weinstein SJ, Inskip PD, Brenner A, Rothman N, Chatterjee N, Gillanders EM, Chanock SJ, Wang SS.

Cancer Causes Control. 2013 Oct;24(10):1885-91. doi: 10.1007/s10552-013-0244-7. Epub 2013 Aug 1.

36.

Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study.

Koshiol J, Sklavos M, Wentzensen N, Kemp T, Schiffman M, Dunn ST, Wang SS, Walker JL, Safaeian M, Zuna RE, Hildesheim A, Pfeiffer RM, Pinto LA.

Int J Cancer. 2014 Jan 15;134(2):411-25. doi: 10.1002/ijc.28354. Epub 2013 Jul 30.

37.

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.

Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.

38.

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.

Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N, Esser MT, Matys K, Meuree A, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Safaeian M; Costa Rican Vaccine Trial Group.

PLoS One. 2013;8(1):e53067. doi: 10.1371/journal.pone.0053067. Epub 2013 Jan 2.

39.

Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).

Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA.

Vaccine. 2012 Dec 17;31(1):165-70. doi: 10.1016/j.vaccine.2012.10.067. Epub 2012 Oct 31.

40.

Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials.

Safaeian M, Ghosh A, Porras C, Lin SW, Rodriguez AC, Schiffman M, Wacholder S, Kemp T, Gonzalez P, Wentzensen N, Esser M, Meuree A, Matys K, Quint W, van Doorn LJ, Sherman ME, Herrero R, Pinto LA, Hildesheim A.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1547-54. doi: 10.1158/1055-9965.EPI-12-0558. Epub 2012 Jul 2.

41.

Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels.

Kemp TJ, Safaeian M, Miner S, Williams MC, Rodriguez AC, Herrero R, Hildesheim A, Pinto LA.

Front Oncol. 2012 Jun 25;2:61. doi: 10.3389/fonc.2012.00061. eCollection 2012.

42.

Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer.

Safaeian M, Hildesheim A, Gonzalez P, Yu K, Porras C, Li Q, Rodriguez AC, Sherman ME, Schiffman M, Wacholder S, Burk R, Herrero R, Burdette L, Chanock SJ, Wang SS.

PLoS One. 2012;7(4):e33619. doi: 10.1371/journal.pone.0033619. Epub 2012 Apr 9.

43.

Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.

Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M; Costa Rica HPV Vaccine Trial (CVT) Group.

Sex Transm Dis. 2011 Oct;38(10):976-82. doi: 10.1097/OLQ.0b013e31822545c0.

44.

Medical history and the risk of biliary tract cancers in Shanghai, China: implications for a role of inflammation.

Andreotti G, Liu E, Gao YT, Safaeian M, Rashid A, Shen MC, Wang BS, Deng J, Han TQ, Zhang BH, Hsing AW.

Cancer Causes Control. 2011 Sep;22(9):1289-96. doi: 10.1007/s10552-011-9802-z. Epub 2011 Jul 9.

45.

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.

Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, Morales J, Wacholder S, Guillen D, Alfaro M, Safaeian M, Burk RD, Schiffman M.

J Infect Dis. 2011 Jul 1;204(1):94-102. doi: 10.1093/infdis/jir209.

46.

Chronic typhoid infection and the risk of biliary tract cancer and stones in Shanghai, China.

Safaeian M, Gao YT, Sakoda LC, Quraishi SM, Rashid A, Wang BS, Chen J, Pruckler J, Mintz E, Hsing AW.

Infect Agent Cancer. 2011 May 2;6:6. doi: 10.1186/1750-9378-6-6.

47.

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA.

Vaccine. 2011 Mar 3;29(11):2011-4. doi: 10.1016/j.vaccine.2011.01.001. Epub 2011 Jan 15.

48.

Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.

Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, Herrero R, Hildesheim A, Viscidi RP, Quint W, Burk RD.

J Natl Cancer Inst. 2010 Dec 1;102(23):1794-804. doi: 10.1093/jnci/djq436. Epub 2010 Nov 23.

49.

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A; Costa Rican Vaccine Trial Group.

J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62. doi: 10.1093/jnci/djq384. Epub 2010 Oct 13.

50.

Determinants of seropositivity among HPV-16/18 DNA positive young women.

Porras C, Bennett C, Safaeian M, Coseo S, Rodríguez AC, González P, Hutchinson M, Jiménez S, Sherman ME, Wacholder S, Solomon D, van Doorn LJ, Bougelet C, Quint W, Schiffman M, Herrero R, Hildesheim A; Costa Rica HPV Vaccine Trial (CVT) Group.

BMC Infect Dis. 2010 Aug 11;10:238. doi: 10.1186/1471-2334-10-238.

Supplemental Content

Loading ...
Support Center